PP_1170x120_10-25-21

Merck

Dr. Julie Gerberding to retire from Merck

Dr. Julie Gerberding to retire from Merck

KENILWORTH, N.J. — Merck announced that Dr. Julie Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022. Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16. “Julie’s accomplishments during

Merck announces new leadership for Human Health business

Merck announces new leadership for Human Health business

KENILWORTH, N.J. — Merck has announced new leadership for its Human Health business. Arpa Garay will lead Human Health Global Marketing, Jannie Oosthuizen will take the reins of Human Health U.S., and Merck is recruiting externally to fill the Human Health International role. In the interim, Deepak Khanna will lead Human Health International. These three positions will

FDA authorizes Merck pill for COVID-19 treatment

FDA authorizes Merck pill for COVID-19 treatment

WASHINGTON — The Food and Drug Administration on Thursday authorized Merck’s COVID-19 pill for certain adults. The authorization for molnupiravir is limited to adults over 18 who have a high risk of severe illness and “for whom alternative FDA-authorized treatment options are not accessible or medically appropriate,” the FDA said in a press release Thursday.

Merck and Ridgeback announce U.S. government to purchase 1.4 million additional courses of molnupiravir

Merck and Ridgeback announce U.S. government to purchase 1.4 million additional courses of molnupiravir

KENILWORTH, N.J. — Merck and Ridgeback Biotherapeutics announced Tuesday that the United States government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA),

Merck reports experimental COVID-19 pill cut deaths, hospitalizations in half when given early

Merck reports experimental COVID-19 pill cut deaths, hospitalizations in half when given early

KENILWORTH, N.J. —Merck announced Friday that it has developed an experimental COVID-19 pill that is said to reduced hospitalizations and deaths by half in people recently infected with the coronavirus. The company said that it would soon ask health officials in the U.S. and around the world to authorize its use. If cleared, Merck’s drug

Merck to acquire Acceleron Pharma

Merck to acquire Acceleron Pharma

KENILWORTH, N.J. — Merck and Acceleron Pharma announced on Thursday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. Acceleron is focused on harnessing the power of the transforming growth factor

Merck names Downing chief communications and public affairs officer

Merck names Downing chief communications and public affairs officer

KENILWORTH, N.J. — Merck announced that Cristal Downing has been appointed chief communications & public affairs officer, a newly created role, effective August 16, 2021. Downing will become a member of Merck’s Executive Team and lead the development, advancement and execution of the company’s communications and public affairs strategy. “Cristal is a transformational leader with

Merck appoints Caroline Litchfield CFO

Merck appoints Caroline Litchfield CFO

KENILWORTH, N.J. — Merck announced Wednesday that Caroline Litchfield has been appointed executive vice president and chief financial officer (CFO), effective April 1, 2021. Litchfield succeeds Robert Davis; as previously announced (link), Davis, Merck’s current CFO, will become president of Merck, effective April 1, 2021, and will become chief executive officer on July 1, 2021.

Mike Nally to leave Merck; Frank Clyburn to lead all Merck Human Health

Mike Nally to leave Merck; Frank Clyburn to lead all Merck Human Health

KENILWORTH, N.J. — Merck announced that Michael Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with

Merck and Gilead working together on HIV treatments

Merck and Gilead working together on HIV treatments

KENILWORTH, N.J. – Gilead Sciences and Merck today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people

Merck to produce Johnson & Johnson COVID-19 vaccine

Merck to produce Johnson & Johnson COVID-19 vaccine

WASHINGTON  — Merck will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine in an effort to expand supply more quickly, the White House reported Tuesday. This announcement comes as the White House looks to ramp up the production of the single-dose vaccine. Officials have said J&J faced unexpected production issues with its vaccine

Kenneth Frazier to retire as Merck CEO; board elects Davis as successor

Kenneth Frazier to retire as Merck CEO; board elects Davis as successor

KENILWORTH, N.J. — Merck announced that Kenneth Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021. Frazier will continue to serve on Merck’s board of directors as executive chairman, for a transition period to be determined by the board. The Merck board of directors has unanimously elected Robert M. Davis,

Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates

Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates

KENILWORTH, N.J. — Merck is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and

1 2 3